Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2025

Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development

Rheumatology (Oxford). 2025;64:1131–1137. doi: 10.1093/rheumatology/keae257

Sichi L,

Frau A,

Piga M,

Floris et al. conducted a monocentric cohort study to assess the impact of biologic treatment on the development of PsA in patients with PsO. Treatment with biologics significantly reduced the likelihood of PsA development, with lower prevalence observed across different biologic classes and patterns of joint involvement.

Keywords:

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis

Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005

Zhao SS,

Riley D,

Hernandez G,

Alam U

Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.

Keywords:

Effective second‑line b/tsDMARDs for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs from the FIRST registry

Rheumatol Ther 2025. Epub ahead of print doi: 10.1007/s40744-025-00747-9

Kanda R,

Kubo S,

Ueno M,

Sakai H,

Kanda et al. investigated the efficacy of second-line b/tsDMARDs in RA patients unresponsive to first-line b/tsDMARDs. Using data from the FIRST registry, the study assessed 687 patients with RA treated with TNFis, IL-6 receptor inhibitors, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin, or JAKis. After propensity score-based adjustment, JAKi showed the highest persistence rate, greatest improvement in CDAI, and highest remission rates at 24 weeks. Among JAKi, UPA was most effective in achieving remission, with a safety profile comparable to other b/tsDMARDs.

Keywords:

Effectiveness of JAK Inhibitors Compared with Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results from a Nationwide Swedish Cohort Study

Arthritis Rheumatol. 2025;77:253–262 doi: 10.1002/art.43014.

Bower H,

Eberhard et al. investigated the effectiveness of JAKi versus bDMARDs on pain reduction in RA patients, using Swedish national register data. JAKi treatment resulted in a significantly greater reduction in pain at three months compared with TNFis, with a higher proportion achieving low pain at 12 months, particularly in those previously treated with multiple bDMARDs.

Keywords:

February 2025

Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies

J Rheumatol 2025. Epub ahead of print doi: 10.3899/jrheum.2024-0923

Ink B,

Lyris N,

Gladman et al. assessed the impact of bimekizumab over 1 year on patient-reported symptoms, HRQoL, and work productivity in patients with PsA who were bDMARD-naïve or TNF-IR. The study showed that bimekizumab treatment resulted in sustained improvements across multiple domains, including pain, fatigue, physical function, and work impairment.